- Home
- About Us
- Industrial
- Product
- News
- Culture
- Houman Resource
- CPC Building
- Investor Relationship
- Contact Us
Founded in 1990, Zhejiang Jingxin Pharmaceutical Co., Ltd. is a listed pharmaceutical company integrating R&D, production and sales. Adhering to the business guideline of “strengthening the main business of pharmaceuticals and developing medical devices”, we adhere to the core values of “pragmatic, innovative, inclusive and win-win”. Jingxin aims to fulfill our duty of “careful protection of health” and to take the lead in psycho-neural and cardiovascular fields.
Up to now, the company has a registered capital of 860 million yuan and total assets of 8.479 billion yuan.The company has more than 3,900 employees,including more than 230 doctors and masters.The company has two headquarters in Xinchang and Hangzhou. It has seven production sites including the plant in Xinchang for finished medicines, the two API plants in Shangyu and Shandong, the TCM production site in Bayannaoer, Inner Mongolia, and the medical equipment production base of Shenzhen and Shenyang. Aside from that, the company also owns a breeding base in Yunnan. In Shanghai, the company has established its own research institute i n the Zhangjiang Hi-Tech Park. Joint ventures and collaberated labs have also been founded over the years in the U.S.A., Denmark, Isereal, Korea as well as other countries.
All along, the company has been adhering to the "Jingxin drug, meticulously made" quality concept. It has passed the new version of GMP certification, the solid preparation production line took the lead in 2006 by passing the German GMP certification. In 2018, it also passed the FDA on-site certification. The company's comprehensive economics have been rapidly improved. It was listed as one of the "Top 100 Chinese Pharmaceutical Industry Brands", "Top 100 Chinese Pharmaceutical Industry" and "Top 100 Chinese Chemical Pharmaceutical Enterprises" for many years. It was recognized as the first batch of " Leading Chinese pharmaceutical companies in the internationalization of preparations", gainging increasing the social popularity and reputation.
The company is a national key high-tech enterprise, with a national enterprise technology center, post-doctoral research station, provincial key enterprise research institute, provincial academician expert workstation, provincial high-tech enterprise R & D center, and Shanghai Research Institute in Shanghai Zhangjiang Hi-Tech Park. It enjoys long-term good communication and cooperation with Shanghai Institute of Pharmaceutical Industry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Zhejiang University and other famous domestic and foreign research institutes, research and development companies, and famous universities. The company is strong in research and technology with fruitful results in R&D. It now has 8 national key new products and is in charge of 9 national Torch Program projects.
Up to 2024, Jingxin has 222 effective patents, including 156 domestic invention patents, 2 US invention patents, reflecting the company's strong research and development capabilities and innovation capabilities.
More
DimdazenilCapsules have been successfully included in the National Medical Insurance Catalogue through medical insurance negotiations.
Salmeterol Fluticasone Powder for Inhalation has been approved for marketing.
The Hangzhou headquarters has been officially put into use.
The "Annual Capacity Expansion Project of 3 Billion Solid Dosage Forms" of Jingxin Xinchang International Health Industry Park has been put into operation.
The innovative drug Dimdazenil Capsules of Class 1 has been approved for marketing.
Inner Mongolia Jingxin Traditional Chinese Medicine Intelligent Manufacturing Digital Production Construction Project has been put into operation.
The Chemical Research Institute has moved into the headquarters in Hangzhou.
Shenzhen Jufeng's Hangzhou factory has started production.
Invest in the establishment of Shandong Jingxin Pharmaceutical Co., Ltd.
The Jingxin Xinchang International Health Industry Park project has officially started construction.
Build a Hangzhou headquarters operation center integrating R&D, production and management.
The first self-developed ANDA product, Colesevelam Hydrochloride Tablets, has been approved and exported to the United States.
20 mg of simvastatin tablets and 0.25 g of cefuroxime axetil tablets have been evaluated by consistency.
The instrument product “stream” show for the first time in China，leading to a new era of neural intervention.
Rosuvastatin calcium tablets (specification 10mg) approved by the State Drug Administration for the issuance of drug registration approval.
5 mg and 10 mg of rosuvastatin calcium tablets and 5 mg of amlodipine besylate tablets have been evaluated by consistency. Among them, 0.25 g of levetiracetam tablets and 50 mg of sertraline hydrochloride tablets are the first to pass the quality and efficacy consistency of generic drugs. Evaluation;
“The research and industrialization of key technologies of statin series lipid-lowering drugs” won the first prize of 2017 Zhejiang Science and Technology Progress Award issued by Zhejiang Provincial People's Government.
The rivastigmine valsartan capsule (specification 1.5mg and 3.0mg), pramipexole hydrochloride tablets (size 0.25mg and 1.0mg) approved by the State Food and Drug Administration for the issuance of drug registration approval.
Solid preparation line passed FDA on-site certification.
The new office building of Jingxin Pharmaceutical Research Institute was officially opened.
Invest in the development of Israeli P2B pharmaceutical preparations.
Invest in Israel's Perflow innovative plugging interventional device.
Invest in the US SPES R&D platform construction project.
The company's technology center was included in the list of the 22nd batch of nationally recognized enterprise technology centers.
Tnvest in MAPI's long-term and safe neuropsychotic preparation technology research and development.
The successful acquisition of Shenzhen Juyi Display Technology Co., Ltd. marks the company's substantial progress in the field of medical devices.
For the first time, we will take the pace of overseas expansion and establish a British joint venture company (SEPS).
The company's sertraline hydrochloride and its preparation projects were included in the National Torch Program Industrialization Demonstration Project.
Levetiracetam and tablets obtained the production approval issued by the State Food and Drug Administration.
The company's first biological product, Bacillus licheniformis live capsule, passed the provincial new product appraisal and was recognized as the international leader in technology.
The company's first class 1.1 innovative drug EVT201 obtained the drug clinical trial approval issued by the State Food and Drug Administration.
"Jing Changle" successfully listed
Acquired Beijing Shunda Sihai Biomedical Co., Ltd. and officially entered the field of biomedicine
Invested in the target assets of Linhe Chinese Medicine Factory in Bayannaoer, Hetao Plain, and established Inner Mongolia Jingxin Pharmaceutical Co., Ltd.
Listed on the Shenzhen Stock Exchange (stock code: 002020)
Established Zhejiang Jingxin Pharmaceutical Co., Ltd.
Established Zhejiang Jingxin Pharmaceutical Factory
Jingxin Pharmaceutical has always adhered to its mission of “careful protection of health" focusing deeply on the fields of neuropsychiatry and cardiovascular health. Innovation is the only path to the long-term development of a pharmaceutical company. Jingxin is committed to pursuing valuable innovation, continuously increasing R&D investment, breaking through key technologies, and driving development through innovation to build core competitiveness.
Jingxin's growth relies on its hard strength, but even more on its soft strength. We will continue to uphold the values of "Pragmatic, Innovative, Inclusive, and Win-win," maintain strategic focus, and concentrate on doing our own work well. Fearless of challenges and steadfast in our efforts, we are determined to pave the way for Jingxin's future success!
About Us Introduction Honor Experience Speech
Houman Resource Concept Society Campus Learn
CPC Building Acitivities Individuals Education
Investor Relationship
Contact Us Manner Marketing Tendering
Chinese
English
